title: Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: analysis of the Okayama Lung Cancer Study Group trial 0007.
abstract: BACKGROUND
  Thoracic radiotherapy (RT) with concurrent chemotherapy may be offered to selected elderly patients with locally advanced non-small cell lung cancer. The Okayama Lung Cancer Study Group (OLCSG) 0007 trial with patients up to 75 years showed that with concurrent RT, docetaxel and cisplatin (DP) chemotherapy was an alternative to mitomycin C, vindesine, and cisplatin (MVP) chemotherapy.
  
  
  METHODS
  Of the 99 patients in the DP arm, 73 were younger than 70 years and 26 were 70 years or older. Of the 101 patients in the MVP arm, 75 were younger than 70 years and 26 were 70 years or older. Overall survival (OS) and progression-free survival (PFS) were calculated using the Kaplan-Meier method and were compared using an early period weighted log-rank test. Toxicities and treatment intensities were compared by χ(2) and t tests, respectively.
  
  
  RESULTS
  OS and PFS tended to be longer in the DP arm versus MVP arm: median OS (months), 27.5 versus 22.9 (p = 0.109) and 25.6 versus 23.4 (p = 0.064) in the ≥70-year and <70-year groups, respectively; median PFS (months), 19.0 versus 11.5 (p = 0.175) and 12.0 versus 9.3 (p = 0.132) in the ≥70-year and less than 70-year groups, respectively. Severe toxicity (neutropenia, esophagitis, and pneumonitis) rates did not differ between age groups. Nevertheless, the absence of statistically significant differences in this retrospective analysis might be due to the small number of patients. Radiation intensity was similar between the groups, but chemotherapy intensity was lower in the ≥70-year group.
  
  
  CONCLUSIONS
  Chemotherapy with concurrent RT may be effective and tolerable in elderly patients with locally advanced non-small cell lung cancer.
authors.affiliation: Department of Respiratory Medicine, Okayama University Hospital, Kitaku, Okayama, Japan. ntakigaw@md.okayama-u.ac.jp
authors.forename: Nagio
authors.initials: N
authors.lastname: Takigawa
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Kiura
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Segawa
authors.forename: Katsuyuki
authors.initials: K
authors.lastname: Hotta
authors.forename: Akihiko
authors.initials: A
authors.lastname: Tamaoki
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Tokuda
authors.forename: Takuya
authors.initials: T
authors.lastname: Nagata
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Watanabe
authors.forename: Kenichi
authors.initials: K
authors.lastname: Gemba
authors.forename: Tomonori
authors.initials: T
authors.lastname: Moritaka
authors.forename: Naokatsu
authors.initials: N
authors.lastname: Horita
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Takeda
authors.forename: Niro
authors.initials: N
authors.lastname: Okimoto
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Takemoto
authors.forename: Keitaro
authors.initials: K
authors.lastname: Matsuo
authors.forename: Tetsu
authors.initials: T
authors.lastname: Shinkai
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tabata
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ueoka
authors.forename: Susumu
authors.initials: S
authors.lastname: Kanazawa
authors.forename: Mitsune
authors.initials: M
authors.lastname: Tanimoto
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy / Q000009:adverse effects / Q000379:methods; D000077143:Docetaxel; D005260:Female; D006801:Humans; D007564:Japan; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage; D011879:Radiotherapy Dosage; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome; D014751:Vindesine / Q000008:administration & dosage
chemical_list: D043823:Taxoids; D000077143:Docetaxel; D016685:Mitomycin; D002945:Cisplatin; D014751:Vindesine